Sasha Ebrahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sasha Ebrahimi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amar U. Kishan
Department of Radiation Oncology, University of California Los Angeles, Los Angeles, USA
1 shared publication - Drew Moghanaki
Department of Radiation Oncology, David Geffen School of Medicine at UCLA , Los Angeles, CA
1 shared publication - Famke L. Schneiders
Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, De Boelelaan 1117, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
1 shared publication - Isabella Pahulu
Department of Epidemiology and Population Health, Stanford University , Stanford, CA
1 shared publication - Jonathan J. Shih
School of Medicine, University of California, San Francisco, San Francisco, CA, United States
1 shared publication - Kekoa Taparra
Department of Health Policy and Management UCLA Fielding School of Public Health Los Angeles California USA
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111599
Efficacy and safety of adrenalectomy and stereotactic ablative radiotherapy (SABR) for adrenal metastases: A systematic review and meta-analysis
- 20 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111599
Open AccessEfficacy and safety of adrenalectomy and stereotactic ablative radiotherapy (SABR) for adrenal metastases: A systematic review and meta-analysis
- Open Access
- 17 February 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions
Background: Given excellent prostate cancer outcomes, comorbidity management is critical to survivorship. While hormone therapy or androgen deprivation therapy (ADT) is a mainstay of treatment, they can negatively impact quality of life and survivorship through cardiovascular, sexual, and metabolic effects. ADT-induced metabolic syndrome causes impaired glucose tolerance, muscle mass loss, and weight gain. This systematic review examined recent randomized clinical trials (RCTs) investigating the impact of diet and weight management strategies on mitigating ADT-related adverse effects. Methods: A systematic review of RCTs (2015-2025) was performed using PubMed/Embase following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. To identify how diet and weight management impacts ADT symptoms, search terms included: “prostate cancer,” “diet,” “nutrition,” “glucagon-like peptide-1 receptor agonists” (GLP-1RA), and “ADT.” Risk of Bias 2 (ROB2) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools evaluated RCT quality. Results: Of 2799 publications, 16 met inclusion/exclusion criteria (range, 23-96 patients/RCT). No RCTs had a high risk of bias or evaluated GLP-1RA. Outcomes included metabolic labs, body composition, and quality of life. Mediterranean and low-carbohydrate diets with exercise reduced cardiovascular and metabolic risk factors, with variable durability. Creatine trended toward increasing lean muscle mass. Multidisciplinary care and community involvement improved accountability and outcome durability. Conclusions: This comprehensive review of diet and ADT in prostate cancer identified nutritional interventions that were safe, feasible, and may be recommended as part of prostate cancer treatment and survivorship. Future RCTs should evaluate optimal diet duration, longer follow-up, multidisciplinary patient support, and novel anti-metabolic therapies like GLP-1RA.
- 17 February 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Open AccessDiet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions
Background: Given excellent prostate cancer outcomes, comorbidity management is critical to survivorship. While hormone therapy or androgen deprivation therapy (ADT) is a mainstay of treatment, they can negatively impact quality of life and survivorship through cardiovascular, sexual, and metabolic effects. ADT-induced metabolic syndrome causes impaired glucose tolerance, muscle mass loss, and weight gain. This systematic review examined recent randomized clinical trials (RCTs) investigating the impact of diet and weight management strategies on mitigating ADT-related adverse effects. Methods: A systematic review of RCTs (2015-2025) was performed using PubMed/Embase following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. To identify how diet and weight management impacts ADT symptoms, search terms included: “prostate cancer,” “diet,” “nutrition,” “glucagon-like peptide-1 receptor agonists” (GLP-1RA), and “ADT.” Risk of Bias 2 (ROB2) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools evaluated RCT quality. Results: Of 2799 publications, 16 met inclusion/exclusion criteria (range, 23-96 patients/RCT). No RCTs had a high risk of bias or evaluated GLP-1RA. Outcomes included metabolic labs, body composition, and quality of life. Mediterranean and low-carbohydrate diets with exercise reduced cardiovascular and metabolic risk factors, with variable durability. Creatine trended toward increasing lean muscle mass. Multidisciplinary care and community involvement improved accountability and outcome durability. Conclusions: This comprehensive review of diet and ADT in prostate cancer identified nutritional interventions that were safe, feasible, and may be recommended as part of prostate cancer treatment and survivorship. Future RCTs should evaluate optimal diet duration, longer follow-up, multidisciplinary patient support, and novel anti-metabolic therapies like GLP-1RA.